Alcaraz L, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C, Mollevi C, Boissière-Michot F, Huesgen P, Overall C, Tartare-Deckert S, Jacot W, Chardès T, Guiu S, Roger P, Reinheckel T, Moali C, Liaudet-Coopman E A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. Theranostics. 2021;11(13):6173-6192. doi:10.7150/thno.58254
Mansouri H, Alcaraz L, Mollevi C, Mallavialle A, Jacot W, Boissière-Michot F, Simony-Lafontaine J, Laurent-Matha V, Roger P, Liaudet-Coopman E, Guiu S Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers (Basel). 2020;12(5). doi:10.3390/cancers12051244
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z
Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo P-E, Azria D, Pèlegrin A, Larbouret C, Chardès T An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer. 2019;145(7):1838-1851. doi:10.1002/ijc.32273
Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy P-J, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br. J. Cancer. 2018;119(1):76-79. doi:10.1038/s41416-018-0142-6
Institut de Recherche en Cancérologie de
